GET DAILY SIGNALSDentsply Sirona (XRAY) Analyst Price Target Implies +34% Gain
Key Takeaways
- The central target reviewed here is $13, the arithmetic mean of roughly a dozen verified analyst price targets collected from individual firms.
- That target sits about 34% above the latest verified close of $9.73 (November 3, 2026), so the implied move is substantial rather than incremental.
- Individual analyst targets span a wide range, from $10 (Leerink Partners and BMO Capital) to $17 (Bank of America and UBS), with a prevailing "Hold" stance.
- Supporting factors include early signs of dental-market stabilization, an expected rebound in EPS (earnings per share), and restructuring efforts.
- The biggest risks are weak demand heading into earnings, repeated guidance cuts, leadership turnover, and declining revenue.
- For more detail, explore Major News, Today's Price Move, the Forecast page, and Earnings coverage for Dentsply Sirona.
- Readers can also explore Trending AI Robots to see automated strategies currently drawing attention.
Analyst Price Targets and Consensus View
Dentsply Sirona Inc. (XRAY) is a dental products and technologies company, and its analyst coverage is broad but heavily weighted toward a neutral view. Reviewing roughly a dozen current, individually attributed targets from firms including Bank of America, UBS, Stifel, Baird, Barrington, Evercore ISI, Wells Fargo, Piper Sandler, Mizuho, Barclays, Leerink Partners, and BMO Capital produces a range of roughly $10 to $17 and an arithmetic mean of about $13, which serves as the central target here.
Views differ sharply. The more bullish targets ($17 from Bank of America and UBS) assume a multi-year recovery takes hold, while cautious targets ($10 from Leerink and BMO) reflect concern about demand and a slower "return to growth." Most firms cluster in the low-to-mid teens with Hold or Market Perform ratings. This is consistent with published aggregate figures that land in the low-to-mid $12 to $13 range, but the central figure is a calculated mean of individual targets, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At a recent close of $9.73, reaching $13 would require a gain of roughly 34% — a substantial move for a large-cap specialty manufacturer. The stock has been under pressure, trading well below its 52-week high of $14.76 and near its 52-week low of $8.32.
The path toward the target depends on whether the company can stabilize revenue (recently around $3.6 billion annually) and expand margins. Analysts expect a modest rebound in EPS for fiscal 2026, but revenue is still forecast to decline year over year. With the next quarterly report due shortly, near-term direction will hinge on actual demand and guidance rather than valuation alone.
What Could Support a Move Toward the Target
- Market stabilization: Several analysts have noted early signs the dental market is stabilizing, which could support a re-rating.
- Earnings recovery: Consensus estimates point to firmer EPS in 2026 after a difficult 2025.
- Restructuring: Cost and portfolio actions, including focus on higher-margin segments, could lift profitability.
- Low expectations: With the shares near multi-year lows and many ratings already cautious, even modestly better results could trigger upward target revisions.
What Could Prevent the Target From Being Reached
- Weak demand: Leerink and Mizuho have both flagged limited expectations for a strong quarter across the dental group.
- Guidance and revenue declines: Revenue is forecast to contract again in 2026, and BMO trimmed its 2027 organic-growth estimate to roughly 0.1%.
- Leadership turnover: A CFO transition and extended turnaround timeline have added execution uncertainty.
- Valuation compression: A negative trailing EPS and a long history of target cuts make multiple expansion harder to sustain.
Technical Levels and Market Structure
The shares remain in a longer-term downtrend, with the 52-week high near $14.76 acting as a major overhead reference and the 52-week low near $8.32 as key support. Between the current price and the $13 target, the stock must first reclaim levels around $10 to $11, which have served as recent resistance and as prior support, before approaching the $12 to $13 zone. A decisive move back above $13 would put the stock closer to the mid-teens area where it traded earlier in 2026.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. The most important near-term catalyst is the company's next earnings report and guidance update, followed by any analyst revisions to targets and ratings. Investors should also watch macroeconomic signals for dental-patient traffic and elective-procedure demand, leadership announcements, and changes to the company's turnaround timeline. None of these guarantees the stock reaches $13, but each will shape the probability-weighted outlook. From what I see, this upcoming report is important because it could shift the entire outlook.
AI Daily Buy/Sell Signals
For traders who prefer a systematic approach, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I’ve found this tool helpful in my own process for spotting shifts in names like Dentsply Sirona without relying solely on manual reviews.
Final Assessment
The central $13 target for Dentsply Sirona (XRAY) reflects the arithmetic mean of roughly a dozen current analyst targets ranging from $10 to $17, implying a substantial gain of about 34% from the latest close near $9.73. The bull case rests on dental-market stabilization, an earnings recovery, and low expectations, while the bear case points to weak demand, declining revenue, and ongoing leadership turnover. With most analysts holding a neutral stance and targets spread widely, the path to $13 is far from assured. Investors should watch the upcoming earnings report, guidance, and any subsequent analyst revisions before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XRAY's RSI Indicator climbs out of oversold territory
The RSI Indicator for XRAY moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 30 of the 42 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 27 of 53 cases over the following month. The odds of a continued upward trend are 51%.
XRAY moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.436) is normal, around the industry mean (4.946). P/E Ratio (-3.564) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.066) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Bitcoin’s Source Code, Pt 1: What Does Open-Source Mean?
What is the definition of consolidation?
What Is Stagflation, and How Does It Impact Economies?
AI Trading Bots: Top 10 Day Traders, Signals Only, on October 20, 2024
TCOM, LU, ZIM, HD, PANW, BILI, PONY, TJX, LOW, SNOW, TGT, BIDU, ZM, BBY, GES | Q1 2025 Earnings Preview: May 19-21, 2025
General Information
a global denal eqipment company
Industry PharmaceuticalsOther
Advertisement